Biohit Oyj revised earnings guidance for the year 2022. For the year, the company revises its EBIT to be positive in 2022 (2021: EUR -1.5 million). The previous guidance for 2022, issued on March 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.01 EUR | +0.50% | 0.00% | +6.63% |
Apr. 15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
Feb. 14 | Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.63% | 32.78M | |
+11.01% | 8.21B | |
-3.44% | 4.68B | |
+5.74% | 2.15B | |
-21.73% | 1.15B | |
-3.15% | 889M | |
-8.36% | 806M | |
-19.75% | 798M | |
-21.82% | 684M | |
-56.02% | 681M |
- Stock Market
- Equities
- BIOBV Stock
- News Biohit Oyj
- Biohit Oyj Revises Earnings Guidance for the Year 2022